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Identification of N-terminal Extracellular Domain
Determinants in Nicotinic Acetylcholine Receptor (nAChR) 6
Subunits That Influence Effects of Wild-type or Mutant 3
Subunits on Function of 62*- or 64*-nAChR*□S
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From the Division of Neurobiology, BarrowNeurological Institute, Phoenix, Arizona 85013
Background: 63*-Nicotinic receptors (nAChRs) are physiologically important but difficult to express heterologously.
Results: Influences of 3 subunits on 63*-nAChR function are impacted by 6 subunit N-terminal domain loop E residues.
Conclusion: There are unexpected roles for the complementary face of the nAChR 6 subunit in receptor function.
Significance:Novelmedicinals acting at new sites on63*-nAChRs could be useful antidepressants and/or smoking cessation
aids.
Despite the apparent function of naturally expressed mam-
malian 6*-nicotinic acetylcholine receptors (6*-nAChR;
where * indicates the known or possible presence of additional
subunits), their functional and heterologous expression has
been difficult. Here, we report that coexpression with wild-type
3 subunits abolishes the small amount of function typically
seen for all-human or all-mouse 64*-nAChR expressed in
Xenopusoocytes.However, levels of function and agonist poten-
cies are markedly increased, and there is atropine-sensitive
blockade of spontaneous channel opening upon coexpression of
6 and 4 subunits with mutant 3 subunits harboring valine-
to-serinemutations at 9- or 13-positions. There is no function
when6 and2 subunits are expressed alone or in the presence
of wild-type or mutant 3 subunits. Interestingly, hybrid
nAChR containing mouse 6 and human (h) 4 subunits have
function potentiated rather than suppressed by coexpression
withwild-type h3 subunits and potentiated further upon coex-
pression with h3V9S subunits. Studies using nAChR chimeric
mouse/human 6 subunits indicated that residues involved in
effects seen with hybrid nAChR are located in the 6 subunit
N-terminal domain. More specifically, nAChR h6 subunit res-
idues Asn-143 and Met-145 are important for dominant-nega-
tive effects of nAChR h3 subunits on h6h4-nAChR func-
tion. Asn-143 and additional residues in theN-terminal domain
of nAChR h6 subunits are involved in the gain-of-function
effects of nAChR h3V9S subunits on 62*-nAChR function.
These studies illuminate the structural bases for effects of 3
subunits on 6*-nAChR function and suggest that unique sub-
unit interfaces involving the complementary rather than thepri-
mary face of 6 subunits are involved.
There are at least six different nicotinic acetylcholine recep-
tor (nAChR)3  subunits (2–7) and three nAChR  subunits
(2–4) expressed in the mammalian central nervous system
(1). nAChR 7 subunits are thought principally to form homo-
pentameric receptors when expressed in heterologous expres-
sion systems, whereas the other indicated subunits are thought
to assemble into heteropentameric structures containing vari-
ous combinations of  and  subunits. nAChR 3 and 5 sub-
units are considered to be “wild cards,” as they do not form
functional receptors when expressed alone or in binary com-
plexes with any other single subunit. However, they seem capa-
ble of integrating as “accessory” subunits into complexes con-
taining at least one other  and one other  subunit. 6*-
nAChR (where the * indicates the known or possible presence
of additional subunits in the complex) are expressed in the
mammalian brain, predominantly in dopaminergic midbrain
regionsimplicatedinpleasure,reward,anddrug(includingnico-
tine) dependence; they modulate dopamine release and could
be involved in schizophrenia and Parkinson disease (2–7).
nAChR 6 and 3 subunit messages share very similar expres-
sion patterns, and studies using knock-out animal and -cono-
toxin sensitivity assessments suggest that 3 subunit incorpo-
ration is important in the assembly and stability of mature
6*-nAChR, which also must have channel functions.
Mammalian 6*-nAChR are thought to naturally exist as
combinations of 6 with 2 alone or with addition of 3 sub-
units and perhaps of 6 and 4 subunits (1, 7). However,
nAChR with these subunit compositions are not easily recre-
ated in functional forms in artificial expression systems (8).
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Coexpression of a human6/4 chimeric subunits with human
4 subunits inXenopus oocytes or HEK-293 human embryonic
kidney cells results in functional receptors, although expression
of wild-type 6 subunits with 4 subunits did not produce
ligand binding and functional 6*-nAChR (9). Chick or rat
nAChR 6 subunits form functional channels when coex-
pressed with h4 subunits in Xenopus oocytes, but the 6 plus
2 subunit combination fails to form functional channels (10).
Chick6 subunits also formed functional receptors when coex-
pressed with chick 2 or 4 subunits in BOSC 23 cells (11).
More recently, Kuryatov et al. (8) reported functional expres-
sion of human64-nAChR inXenopus oocytes and formation
of ligand-binding (nonfunctional) aggregates of 62-nAChR.
Their study also suggested that 3 subunits may facilitate 6*-
nAChR trafficking to the cell membrane.
Recently (12), it was observed that coexpression with a large
excess of humannAChRwild-type3 subunits has a dominant-
negative effect on the function of human 6*-nAChR, whereas
coexpression with a large excess of human mutant 3 subunits
(valine 273 to serine at position 9 in the putative second trans-
membrane domain; 3V273S 3V9S) potentiates the function
of human 62*- and 64*-nAChR. This observation is sur-
prising, because knock-out studies strongly suggest that the
naturally expressed murine 6*-nAChR containing 2 and 3
subunits are functional and that 6 and 3 subunits are needed
to show sensitivity of these receptors to certain -conotoxins
(4–7).
To re-explore and expand on the prior findings, we further
characterized human (h) or mouse (m) 63*-nAChR heter-
ologously expressed inXenopus oocytes. Further study employ-
ing hybrid nAChR containing subunits from different species,
and use of chimeric subunits having sequences for a given sub-
unit from different species to guide finer site-directed
mutagenesis studies, led us to find unexpectedly that amino
acid residues in the N-terminal domain of 6 subunits influ-
ence sometimes the dominant-negative effects of wild-type 3
subunits and are involved in gain-of-function effects of mutant
3V9S subunits on 6*-nAChR function. Hence, these results
suggest that coassembly of 3 with 6 and 2 subunits to form
functional nAChR is determined by the 6 subunit N-terminal
extracellular region. These results also suggest that a novel
interface between nAChR subunits exists and can influence
subunit assembly and receptor function.
EXPERIMENTAL PROCEDURES
Chemicals—All chemicals for electrophysiology were ob-
tained from Sigma. Fresh agonist (acetylcholine or nicotine)
and antagonist (atropine or mecamylamine) stock solutions
were made daily in Ringer’s solution and diluted as needed.
Wild Type, Chimeric, or Point Mutation nAChR Subunits—
cDNAs corresponding to humannAChR6 (h6),2 (h2),3
(h3), or 4 (h4) subunits were excised from vectors contain-
ing them and subcloned into the oocyte expression vector
pGEMHE. Similarly, cDNAs representing mouse nicotinic
receptor 6 (m6), 2 (m2), 3 (m3), or 4 (m4) subunits
(kind gifts from Dr. Jerry A. Stitzel, Department of Integrative
Physiology, Institute for BehavioralGenetics, University of Col-
orado, Boulder) were subcloned into pGEMHE. Fully synthetic
nAChR h2 subunit with nucleotide sequences optimized for
better heterologous expression (h2opt supplemental Fig. 1)
was generated (GENEART, Burlingame, CA), subcloned into
the pCI vector (Promega, San Luis Obispo, CA), and used in
some studies, and although levels of function in complexes con-
taining optimized 2 subunits were generally slightly higher,
the source of 2 subunit did not materially affect outcomes.
Two chimeric nAChR subunits m6(1–350)/h6(351–494)
and m6(1–236)/h6(237–494) were constructed as sketched
in Fig. 1 and as described in detail in the supplemental material.
Mutations in the m3 (V279S and V283S) or h3 (V273S and
V277S) subunit transmembrane domain II 9- (V9S) or 13
(V13S)-positionwere introduced in the pGEMHEbackground
using the QuikChange II site-directed mutagenesis kit (Strat-
agene, La Jolla, CA) and also confirmed. Similarly, mutations in
the N-terminal domain of the human nAChR 6 subunit
(N91K, K94R, K114N, N143D, M145V, N91K/K94R, and
N143D/M145V)were introducedusing theQuikChange II site-
directed mutagenesis kit. Primers used for mutagenesis are
listed in supplemental Table S1. Construct integrity of all sub-
units was confirmed by sequencing.
In Vitro Transcription—All pGEMHE plasmids were linear-
ized immediately downstream of the 3-polyadenylation
sequence. NheIwas used to linearizem6,m2,m3,m3V9S,
m3V13S, m4, h6, h3, h3V9S, h3V13S, h4, h6N91K,
h6K94R, h6K114N, h6N143D, h6M145V, h6N91KK94R,
h6N143DM145V, m6(1–350)/h6(351–494) and m6(1–
236)/h6(237–494) subunit containing plasmids. SbfIwas used
to linearize h2 subunits. CappedmRNAwas transcribed from
linearized plasmids in a reactionmixture (25l) containing 1
transcription buffer, 1.6mM rNTPs (Promega, San LuisObispo,
CA), 0.5 mM 7m-CAP (New England Biolabs, Ipswich, MA), 1
l of RNasin Plus (New England Biolabs), and 1 l of T7 RNA
polymerase (New England Biolabs) following standard proto-
cols. Integrity and quality of the cRNA were checked by elec-
trophoresis and UV spectroscopy.
Oocyte Preparation and cRNA Injection—Female Xenopus
laevis (Xenopus I, AnnArbor,MI) were anesthetized using 0.2%
Tricaine methanesulfonate (MS-222). Ovarian lobes were sur-
gically removed from the frogs and placed in an incubation
solution that consisted of (in mM) 82.5 NaCl, 2.5 KCl, 1 MgCl2,
1 CaCl2, 1 Na2HPO4, 0.6 theophylline, 2.5 sodium pyruvate, 5
HEPES, 50 mg/ml gentamycin, 50 units/ml penicillin, and 50
g/ml streptomycin, pH 7.5. The frogs were allowed to recover
from surgery before being returned to the incubation tank. The
lobes were cut into small pieces and digested with 0.08Wun-
sch units/ml liberase Blendzyme 3 (Roche Applied Science)
with constant stirring at room temperature for 1.5–2 h. The
dispersed oocytes were thoroughly rinsed with incubation
solution. Stage VI oocytes were selected and incubated at
16 °C before injection. Micropipettes used for injection were
pulled from borosilicate glass (Drummond Scientific,
Broomall, PA) using a Sutter P87 horizontal puller, and the
tips were broken with forceps to40 m in diameter. cRNA
was drawn up into the micropipette and injected into
oocytes using a Nanoject microinjection system (Drum-
mond Scientific) at a total volume of 60 nl. To express
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nAChR in oocytes, about 4 ng of cRNA corresponding to
each nAChR subunit was injected.
Oocyte Electrophysiology—Two to 7 days after injection,
oocytes were placed in a small volume chamber and continu-
ously perfused with oocyte Ringer solution, which consisted of
(inmM) 92.5 NaCl, 2.5 KCl, 1 CaCl2, 1MgCl2, and 5HEPES, pH
7.5. The chamberwas grounded through an agarose bridge. The
oocytes were voltage-clamped at 70 mV (unless otherwise
noted) to measure agonist-induced currents using Axoclamp
900A and pClamp 10.2 software (Axon Instruments, Sunny-
vale, CA). The current signal was low-pass filtered at 10Hzwith
the built in low-pass Bessel filter in the Axoclamp 900A and
digitized at 20 Hz with Axon Digidata 1440A and pClamp10.2.
Electrodes contained 3MKCl and had a resistance of 1–2mego-
hms. Drugs (agonists and antagonists) were prepared daily in
bath solution. Drugwas applied using aValveLink 8.2 perfusion
system (Automate scientific, Berkeley, CA). 1 M atropine was
always coapplied for acetylcholine (ACh)-based recordings to
eliminate muscarinic AChR (mAChR) responses. All electro-
physiological measurements were conducted or checked in at
least two batches of oocytes.
Experimental Controls—Injection of cRNA corresponding to
one subunit alone or pairwise combinations of 3 or 3V9S or
3V13S subunits with either a subunit or2 or4 or chimeric
subunits (10–12 ng of total cRNA) did not result in the expres-
sion of functional nAChR. Current responses to 100 M nico-
tine were less than 5–20 nA (data not shown).
Data Analyses—Rawdatawere collected and processed in part
using pClamp 10.2 (Molecular Devices, Sunnyvale, CA) and a
spreadsheet (Excel; Microsoft, Bellevue, WA), using peak current
FIGURE 1. A, sequence alignment for mouse (m) or human (h) nAChR 6 subunits (GenBankTM NP_004189.1 (Homo sapiens) and NP_067344.2 (Musmusculus);
single letter code, numbering begins at translation start methionine). Symbols below sequences indicate fully (*), strongly (:) or weakly (.) conserved residues,
and the lack of a symbol indicates amino acid divergence, and boldface type in h6 subunit indicates residues given prime attention in mutagenesis studies.
Underlining in the h6 subunit sequence indicates putative transmembrane domains. Underlined and italicized type in the h6 subunit indicates putative
domains involved in ligand binding (loops A–C), and boldface and italicized type in the m6 subunit indicates junctions for chimeric subunits. B, schematic
diagrams of wild-type, human, or mouse 6 subunits or chimeric subunits. Notations are: N N-terminal domain; I, II, III, or IV respective transmembrane
domains; C-loop cytoplasmic loop; C C terminus.
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amplitudes as measures of functional nAChR expression and
results pooled across experiments (mean  S.E. for data from at
least three oocytes). Assessment of true Imax values for different
nAChR subunit combinations was made based on complete con-
centration-response relationships, in which mean peak current
amplitudes at specified ligand concentrations were fit to the Hill
equation or its variants using Prism 4 (GraphPad Software, San
Diego). F-tests (p  0.05 to define statistical significance) were
carried out to compare the best fit values of logmolar EC50 values
across specific nAChR subunit combinations. There are limita-
tions in the ability to compare levels of functional nAChR expres-
sion, even though we injected similar amounts of RNA for all
constructs (13, 14).Wemadenoattempt tomeasureor control for
subunit combination-specific effects, but whenever preliminary
studies revealed possible differences in peak current amplitudes,
the findingswere further confirmed across different subunit com-
binations using the same batch of oocytes and the same time
betweencRNAinjectionand recording.Wheneverwemake state-
ments about results comparing ligand potencies and efficacies
across subunit combinations, theobservations are clear and signif-
icant (one-way analyses of variance followed by Tukey’s multiple
comparison tests).
RESULTS
Wild-type orMutant nAChR3 Subunits from Either Humans
orMice Incorporate into64*-nAChR
In initial studies (Fig. 2A), coexpression of nAChR wild-type
h6 and h4 subunits produced nicotinic responses in only
about 3–5%of injected oocytes, and functional responses to 100
M ACh when present were very modest (22 3 nA; Table 1).
Responses to nicotine were less reliable (Table 1). Coexpres-
sion with wild-type h3 subunits suppressed the modest
responses to 100MACh (8.4 1.0 nA; Fig. 2A). By contrast,
coexpression with mutant h3V9S subunits significantly
increased nicotinic responses to 100 M ACh (290 19 nA),
and nearly every oocyte injected with nAChR h6, h4, and
mutant h3V9S subunits expressed functional nAChR (Fig.
2A and Table 1).
Although the small amplitudes of current in the few oocytes
that yielded functional receptors when injected with cRNA
encoding nAChR h6 and h4 subunits plus wild-type h3
subunits confounded detailed analyses, studies done compar-
ing nicotine andACh efficacies and apparent potencies done on
the same day after injection of the same batch of oocytes indi-
cated that these agonists were equally efficacious (p 	 0.05)
(Table 1) at h6h4h3V9S-nAChR. Also, ACh and nicotine
were equally potent at h6h4h3V9S-nAChR, yielding EC50
values of 0.43 and 0.42 M, respectively (Fig. 2B and Table 1).
Our studies also demonstrated that there alsowas emergence of
receptor function when oocytes were injected with cRNA for
nAChR h6 and h4 subunits along with h3V13S subunits
(Fig. 2C and Table 1). Apparent potency and efficacy for nico-
tine did not differ across 9 and 13 3 subunit mutations (EC50
values of 0.42 and 0.30 M, respectively). However, the EC50
value for ACh of 1.2M at h6h4h3V13S-nAChR differs sig-
nificantly (p 0.0011) from that of 0.43M at h6h4h3V9S-
nAChR, and average ACh efficacy also was lower for the former
set of receptors (Table 1).
Difficulties in expressing functional 6*-nAChR from
human subunits gave us pause, and so we undertook studies
of 6*-nAChR heterologously expressed from mouse sub-
units, because the literature strongly suggests that naturally
expressed mouse 6*-nAChR are functional (2–7). Many
oocytes injected with cRNA encoding nAChRwild-typem6
FIGURE 2. Functional properties of h6h4*-nAChR. A,mean peak inward
current amplitude (S.E.; abscissa; nA) elicited by oocytes expressing the
indicated human nAChR subunit combinations in response to application of
100 M ACh. The level of nAChR function in oocytes expressing h6 and
h4 subunits is reduced by addition of wild-type h3 subunits but
increased in the presence of h3V9S subunits (p  0.05). B and C, results
averaged across experiments were used to produce concentration-re-
sponse curves (ordinate  mean normalized current  S.E.; abscissa 
ligand concentration in log M) for responses to ACh (E) or nicotine (f) as
indicated for oocytes expressing nAChR h6 and h4 subunits with either
h3V9S (B) or h3V13S (C) subunits. Concentration-response curves for
ACh and nicotine are almost superimposable for oocytes expressing h6,
h4, and h3V9S subunits, but EC50 values for ACh and nicotine are differ-
ent (p  0.0001) for oocytes expressing h6, h4, and h3V13S subunits
(see Table 1 for parameters).
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and m4 subunits yielded functional nicotinic responses
(Fig. 3), but coinjection of wild-type m3 subunits failed to
yield oocytes that responded to nicotinic agonists (Table 1).
As with human subunits, oocytes expressing nAChR m6
and m4 with m3V9S or m3V13S subunits yielded rela-
tively large responses to nicotinic agonists (Fig. 3 and Table
1). Agonist concentration-response curves (Fig. 3) reveal
that ACh and nicotine sensitivities are 100–400-fold higher
for m6m4m3V9S- or m6m4m3V13S-nAChR than
for m6m4-nAChR (Fig. 3).
These results indicated that both wild-type 3 and mutant
3V9S or 3V13S subunits incorporate into at least some com-
plexes containing 6 and 4 subunits. Incorporation of 3 sub-
unitshasadominant-negativeeffect, reflectedby loweringof levels
of functional receptors (again, assuming that peak current ampli-
tudes are legitimate proxies for functional nAChR expression lev-
els, with the caveats about this interpretation mentioned under
“Experimental Procedures: Data Analyses.” By contrast, incorpo-
rationof thenAChR3V9S or3V13S subunit produces a gain-of-
function effect reflected by an increase in agonist sensitivity and in
absolute levels of functional receptor expression.
There was no functional expression represented by nico-
tinic agonist-induced current responses in oocytes express-
ing nAChR 6 and 2 subunits alone, in combination with
wild-type 3 subunits, or in combination with either mutant
3V9S or 3V13S subunits from either human or mouse
(Table 1). This confounded the ability to interpret results,
but they do indicate that coexpression with mutant 3V9S or
3V13S subunits does not have a gain-of-function effect on
62*-nAChR from either species, contrary to effects on
64*-nAChR.
StudiesUsingHybridnAChRContainingSubunits fromDifferent
Species Indicate Formsof These6*-nAChR intoWhichnAChR
Wild-typeorMutant3SubunitsCan Incorporate
For a given nAChR subunit (6, 2, 4, and 3) across
species, amino acid residues are nearly perfectly matched in
FIGURE 3. Functional properties of m6m4*-nAChR. Results averaged
across experiments were used to produce concentration-response curves
(ordinatemeannormalized current S.E.; abscissa ligand concentration
in log M) for responses to ACh (A) or nicotine (B) as indicated for oocytes
expressing nAChR m6 and m4 subunits alone (f) or with either m3V9S
(F) or m3V13S (‚) subunits. Leftward shifts in agonist concentration-re-
sponse curves are evident for functional nAChR containing m3V9S or
m3V13S subunits (p0.0001;91- and130-fold, respectively, forAChand
370- and 100-fold, respectively for nicotine). See Table 1 for parameters.
TABLE 1
Parameters for agonist action at nAChR containing human or mouse 6 subunits
Potencies (micromolar EC50 values with 95% confidence intervals), Hill coefficients (nH S.E.), mean S.E. efficacies (Imax in nA), and concentrations wheremaximal peak
current amplitudes (Imax) are achieved (in M) are provided for the indicated agonist (ACh or nicotine) acting at nAChR composed of the indicated subunits derived from
the specified species and from the indicated number of independent experiments (n) based on studies as shown in the figures.1 or2 indicates a significant (p  0.05)
increase or decrease, respectively, in potency or efficacy of the indicated agonist at the indicated nAChR subtype relative to nAChR containing the same subunits but in the
absence of the indicated3 subunit;Œ or indicates a significant increase or decrease, respectively, in indicated agonist potency or efficacy at the indicated nAChR subtype
relative to nAChR containing the same subunits in the presence wild-type 3 subunits, and „ or … indicates a significant increase or decrease, respectively, in potency or
efficacy of the indicated agonist at the indicated nAChR containing3V13S subunits relative to the same complex containing3V9S subunits. Note that no responses or very
rare and then small responses were seen for the following subunit combinations (n 9 each) to ACh or nicotine: h6 h2 alone or with h3 or h3V9S or h3V13S; and
m6  m2 alone or with m3 or m3V9S or m3V13S.  indicates that absent or inconsistent functional responses in two-electrode voltage clamp studies precluded
determination of the parameter of interest.
Drug nAChR subunit combinations
Potency Peak response
n EC50 (95% CI) nH S.E. n Mean Imax S.E. Imax concentration
M nA M
ACh h6 h4 9 – – 3 22 3 100
h6 h4 h3 9 – – 9 – –
h6 h4 h3V9S 9 0.43 (0.34–0.54)1Œ 0.69 0.04 11 2100 2201Œ 101Œ
h6 h4 h3V13S 3 1.2 (0.66–2.3)1 Œ … 0.65 0.10 3 910 1501Œ … 101Œ
m6m4 3 38 (25–58) 0.72 0.09 3 65 25 1000
m6m4m3 9 – – 9 – –
m6m4m3V9S 4 0.42 (0.25–0.71)1Œ 0.57 0.08 3 2100 1901Œ 1001Œ
m6m4m3V13S 4 0.30 (0.22–0.41)1Œ 0.71 0.07 4 2400 4201Œ 1001Œ
Nicotine h6 h4 9 – – 9 – –
h6 h4 h3 9 – – 9 – –
h6 h4 h3V9S 5 0.42 (0.26–0.68)1Œ 0.70 0.19 8 1900 3401Œ 101Œ
h6 h4 h3V13S 4 0.30 (0.24–0.37)1Œ 0.96 0.08 4 1600 541Œ 101Œ
m6m4 3 26 (18–38) 0.65 0.13 5 27 7 1000
m6m4m3 9 – – 9 – –
m6m4m3V9S 6 0.07 (0.04–0.10)1 Œ 0.89 0.14 7 2500 2501Œ 101Œ
m6m4m3V13S 4 0.26 (0.19–0.36)1Œ … 0.79 0.08 4 3000 3601Œ 101Œ
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transmembrane domains, but there are some differences in
other regions of the N terminus, first extracellular domain,
and in the second, large cytoplasmic loop. We hypothesized
that switching between mouse and human 6 plus 2 or 4
subunits would lead to formation of functional 6*-nAChR
and/or 6*-nAChR with function influenced by 3 subunits.
Human nAChR 6 Subunits CoexpressedWith m4 (but Not
Withm2) and h3V9S Subunits Produce Functional Receptors—
Oocytes expressing h6 plus eitherm2 orm4 subunits alone
or additionally coexpressing h3 subunits did not respond
appreciably to nicotinic agonists nor were there responses in
oocytes coexpressing h6, m2, and h3V9S subunits (Table
2). However, coexpression of h6, m4, and mutant h3V9S
subunits yielded oocytes with functional nicotinic responses
(40-nA peak response, see Fig. 4A and Table 2).
Mouse nAChR 6 Subunits Coexpressed with h4 (but Not
with h2) andm3V9S Subunits Produce Functional Receptors—
Coexpression with m3V9S subunits significantly increased
nicotinic responses in oocytes also expressing m6 and h4
subunits (1022-nA peak response, Fig. 4A, Table 2),
although there was not formation of functional m6h4- or
m6h4m3-nAChR. Also, there was no appreciable func-
tion in oocytes expressing m6 plus h2 subunits alone or in
the additional presence of wild-type m3 or m3V9S sub-
units (Table 2).
Mouse nAChR 6 Subunits Coexpressed with h2 and
h3V9S (but Not with h3) Subunits Produce Functional
Receptors—There is functional nAChR expression in oocytes
expressing nAChR m6, h2, and mutant h3V9S subunits
(Fig. 4B and Table 2) but not for hybrid m6h2h3-
FIGURE 4. Functional properties of hybrid 6*-nAChR. Concentration (abscissa; log M)-response (ordinatemean normalized current S.E.) curves are
shown for responses as follows. A, to nicotine for oocytes expressing h6m4h3V9S- (E) or m6h4m3V9S- (F) nAChR; B, to ACh (E) or nicotine (f) for
oocytes expressingmh2h3V9S-nAChR; C, to nicotine for oocytes expressing nAChRm6 and h4 subunits with either h3 (f) or h3V9S (E) subunits; or
D, to nicotine for oocytes expressing nAChR h6, m4, and m3V9S subunits. A leftward shift in the nicotine concentration-response curve is evident for
functional nAChR containing h3V9S subunits relative to nAChR containing wild-type h3 subunits (p 0.0001;173-fold). See Table 2 for parameters.
TABLE 2
Parameters for drug action at hybrid 6* nAChR
Potencies (micromolar EC50 values with 95% confidence intervals for ACh or nicotine effects), Hill coefficients (nH  S.E.), mean  S.E. peak response (Imax in nA), and
concentrations where maximal peak current amplitudes (Imax) are achieved (in M) are provided for the indicated agonist (ACh or nicotine) acting at nAChR composed of
the indicated subunits derived from the specified species and from the indicated number of independent experiments (n) based on studies as shown in the figures.1 or2
indicates a significant (p 0.05) increase or decrease, respectively, in potency of or peak response elicited by the indicated agonist at the indicated nAChR subtype relative
to nAChR containing the same subunits but in the absence of the indicated 3 subunit.Œ or indicates a significant increase or decrease, respectively, in indicated agonist
potency or peak response at the indicated nAChR subtype relative to nAChR containing the same subunits in the presence wild-type 3 subunits. Note that no or very rare
and then small responses were seen for the following subunit combinations (n 9 each) to nicotine: h6m2 alone or with m3, h3, h3V9S, or m3V9S; h6m4
alone or with h3 or m3; m6 h2 alone or with m3, h3, or m3V9S; m6 h4 alone or with m3. indicates that absent or inconsistent functional responses
in two-electrode voltage clamp studies precluded determination of the parameter of interest.
Drug nAChR subunit combinations
Potency Peak response
n EC50 (95% CI) nH S.E. nH n Mean Imax S.E.) Imax concentration
M nA M
Nicotine m6 h2 h3V9S 4 0.03 (0.02–0.05)1Œ 0.67 0.07 4 280 501Œ 11Œ
h6m4 h3V9S 3 0.27 (0.1–0.73)1Œ 0.46 0.09 3 40 21Œ 101Œ
h6m4m3V9S 5 0.06 (0.03–0.15)1Œ 0.48 0.08 5 600 1201Œ 101Œ
m6 h4 h3 7 14 (9.6–21)1 0.7 0.08 8 57 71 10001
m6 h4 h3V9S 3 0.08 (0.03–0.02)1Œ 0.53 0.14 3 1600 981Œ 101Œ
m6 h4m3V9S 3 0.42 (0.28–0.64)1Œ 0.69.08 3 1000 121Œ 101Œ
ACh m6 h2 h3V9S 4 0.34 (0.18–0.62)1Œ 0.52 0.07 4 300 901Œ 1001Œ
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nAChR. m6h2h3V9S-nAChR have maximal responses
of 300 nA at 100 M ACh and at 1 M nicotine, and EC50
values are 0.34 M for ACh and 0.03 M for nicotine (Fig. 4B
and Table 2). Concentration-response curves show little to
no evidence of what would be expected to be low efficacy,
low agonist sensitivity responses that could be attributed to
m6h2-nAChR (Fig. 4B). These studies suggest that the
presence of m6 instead of h6 subunits is key to the func-
tion of m6h2h3V9S-nAChR.
Mouse nAChR 6 Subunits Coexpressed with nAChR h4
and h3 Subunits Produce Functional Receptors with Increased
Agonist Sensitivity and Responsiveness—Hybrid nAChR pro-
duced in oocytes expressing m6, h4, and h3 subunits have
functional responses to nicotinic agonists that are elevated rel-
ative to the negligible to no levels of function observed for
m6h4-nAChR (Table 2 and Fig. 4C). Furthermore, coexpres-
sion with mutant h3V9S subunits significantly increases nico-
tinic responses of oocytes also expressing m6 and h4 sub-
units (Fig. 4C and Table 2), as is the case for oocytes expressing
h6, h4, and h3V9S subunits or m6, m4, and m3V9S
subunits. Pairwise comparisons show that differences in ampli-
tudes of responses to nicotine are statistically significant (p 
0.001) between m6h4h3- and m6h4h3V9S-nAChR
(60 and1600 nA, respectively; Table 2).Moreover, nicotine
potency is increased for m6h4h3V9S-nAChR (EC50 0.08
M) relative to that for m6h4h3-nAChR (EC50  14 M;
Table 2). These results indicate that both wild-type 3 and
mutant h3V9S subunits incorporate into at least some com-
plexes containing m6 and h4 subunits. However, although
mutant h3V9S subunits have the reasonably expected gain-of-
function effect, wild-type h3 subunits have potentiation
rather than an expected, dominant-negative effect. These stud-
ies again suggest importance of m6 instead of h6 subunits in
these effects.
Human nAChR 6 Subunits Coexpressed with nAChR m4
(but Not with m2) and m3V9S Subunits Produce Functional
Receptors—There is no appreciable function of nAChR in
oocytes expressing h6 plus either m2 or m4 subunits alone
or in the additional presence of m3 subunits nor does coex-
pression with m3V9S subunits produce functional nAChR in
oocytes also expressing h6 and m2 subunits (Table 2). How-
ever, coexpression with mutant m3V9S subunits significantly
increases nicotinic responses in oocytes also expressing h6
and m4 subunits (600-nA peak response, nicotine EC50 
0.06 M; Fig. 4D and Table 2).
Evidence for Spontaneous Opening of6*-nAChR Containing
Mutant3V9S or3V13S Subunits
To eliminate possible contributions of muscarinic AChRs to
responses in oocytes expressing nAChR 6 and other subunits,
ACh always was applied in the presence of 1 M atropine, a
muscarinic receptor antagonist that at higher concentrations
also can noncompetitively block nAChR function. To help
define specificity of agonist action, additional studies involved
regular assessment of effects on nAChR function of the nAChR
antagonist, mecamylamine, which also acts noncompetitively
through the open channel block. Effects of atropine or mecam-
ylamine alone were absent when assessed using oocytes
expressing any combination of wild-type nAChR subunits from
any species (data not shown). However, exposure to atropine or
mecamylamine alone resulted in what seemed to be outward
currents in oocytes expressing 6*-nAChR containing 3V9S
or 3V13S subunits (Table 3). These effects were reversible, in
that effects on currents ceased when atropine or mecamyl-
amine were removed. They also were typically concentration-
dependent, in that the magnitudes of the apparent outward
currents were largest at the highest concentrations of atropine
or mecamylamine (Fig. 5).
Inward currents elicited by nicotinic agonists from oocytes
expressing nAChR 6 and 2 or 4 subunits in the presence of
mutant3 subunits were actually reversed to apparent outward
currents (relative to base-line levels) in the presence of added
atropine ormecamylamine, evenwhen agonist was first applied
alone prior to application of agonist in the presence of antago-
nist. These phenomena made it evident that atropine and
mecamylamine were in fact blocking not just inward current
responses to agonists but that they also were blocking resting
inward currents rather than inducing outward currents. Our
interpretation of these results is that 6*-nAChR also contain-
ingmutant 3 subunits and that had large functional responses
to nicotinic agonists has a finite level of spontaneous channel
opening that contributes to a resting inward current. This
inward current can be ceased in the presence of adequately high
concentrations of atropine or mecamylamine thanks to their
TABLE 3
Parameters for antagonist action at nAChR containing 6 subunits
Potencies (micromolar IC50 values with 95% confidence intervals), Hill coefficients (nH S.E.), mean S.E. efficacies (Imax in nA), and concentrations wheremaximal peak
current amplitudes (Imax) are achieved (in M) are provided for the indicated antagonist (atropine or mecamylamine) acting at nAChR composed of the indicated subunits
derived from the specified species and from the indicated number of independent experiments (n) based on studies as shown in figures.  indicates a significant decrease in
potency or efficacy of the indicated antagonist at the indicated nAChR containing3V13S subunits relative to the same complex containing3V9S subunits. indicates that
absent or inconsistent functional responses in two-electrode voltage clamp studies precluded determination of the parameter of interest.
Drug nAChR subunit combinations
Potency Peak response Spontaneous
openingn IC50 (95% CI) nH S.E. n Mean Imax S.E. Imax concentration
M nA M % total
Atropine h6 h4 h3V9S 5 11 (5.7–21) 1.2 0.62 5 500 76 1000 19
h6 h4 h3V13S 4 35 (30–41) 1.1 0.06 3 630 81 1000 41
m6m4m3V9S 3 6.1 (1–36) 1.1 0.91 3 450 210 1000 15
m6m4m3V13S 3 7.8 (1.3–48) 1.6 2.8 3 120 56 1000 4
m6 h2 h3V9S 3 – – 3 42 6 1000 13
m6 h4 h3V9S 3 11 (5.7–21) 1.20 0.13 3 230 7.9 1000 13
Mecamylamine h6m4m3V9S 4 18 (12.6–25) 1.07 0.17 4 300 110 1000 33
m6(1–350)/h6(351–494) h4 h3V9S 3 – – 3 16 1.6 100 10
m6(1–236)/h6(237–494) h4 h3V9S 3 4.4 (0.06–309) 1.8 3.62 3 46 14 100 8
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open channel blocking abilities. It is not uncommon for gain-
of-function mutations in second transmembrane domains of
nAChR subunits to confer spontaneous channel opening to
nAChR that contain those subunits (1). This means that atro-
pine or mecamylamine potencies when acting alone (Table 3)
actually aremeasures of ligand antagonist IC50 values, and addi-
tional studies assessing effects of these agents in block of ago-
nist-induced responses yield similar IC50 values (data not
shown). Antagonist potency determinations (IC50 values; typi-
cally 10 M for both ligands) for atropine or mecamylamine
are summarized in Table 3.
The results also can be used to estimate the number of
nAChR that are spontaneously open. For example, at maxi-
mally efficacious concentrations, the atropine-alone sensitive
component of its effect plus the inward current response to a
full agonist (42 nA/(42 280 nA); Tables 2 and 3) indicate that
about 13% of m6h2h3V9S-nAChR is spontaneously open
even in the absence of agonist. Similar calculations indicate that
4–41% of 6*-nAChR containing 3V9S or 3V13S subunits
are spontaneously open (Tables 1–4).
Contributions of nAChR6 Subunit N-terminal Domain to
Effects of nAChRWild-type orMutant3 Subunits on Function
of6*-nAChR
Deviating from the predominant, dominant-negative effect
of nAChR 3 subunits on any function of 64-nAChR, there
is facilitation of function by nAChR h3 subunits in
m6h4h3-nAChR (Table 2 and Fig. 4).Moreover, deviating
from the predominant absence of function for 62-,
623-, and 623V9S- or 623V13S-nAChR, nAChR
h3V9S subunits exert a gain-of-function effect in
m6h2h3V9S-nAChR (Table 2 and Fig. 4). These effects
could only be attributed to the presence of nAChR m6
instead of h6 subunits in these receptors. Furthermore, the
strongest indication of a gain-of-function effect of mutant
3 subunits on 62*-nAChR function comes from studies
of hybrid receptors containing m6, h2, and h3V9S sub-
units and are not seen for complexes instead containing h6
subunits. To understand the bases for these effects, we
extended our studies to work using chimeric mouse/human
6 nAChR subunits.
Coexpression of Chimeric m6(1–350)/h6(351–494)
nAChR Subunits in Oocytes with nAChR h4 and Either Wild-
type h3 or Mutant h3V9S Subunits Produces Functional
nAChR—There is functional expression represented by nico-
tinic agonist-induced current responses in oocytes expressing
nAChR chimericm6(1–350)/h6(351–494) subunits in com-
bination with h4 and h3 or h3V9S subunits (Fig. 6 and
Table 4). These results indicate that the nAChR 6 subunit
region from cytoplasmic loop residue Pro-350 through to the C
terminus does not strongly influence effects of wild-type 3
subunits and has a limited influence on the effects ofmutant3
subunits on function of64*-nAChR. Reciprocally, the results
suggested that the region N-terminal to Pro-350 is likely to
account for differences in effects of wild-type or mutant 3
subunits on function of h6h4*-nAChR relative to effects on
function of m6h4*-nAChR.
Coexpression of nAChR Chimeric m6(1–236)/h6(237–
494) Subunits inOocytes with h4 and Either nAChRWild-type
h3 orMutant h3V9S Subunits Produces FunctionalReceptors—
To further narrow the search for the region of the nAChR 6
subunit important for interactions with wild-type ormutant3
subunits, we assessed function of nAChR-containing chimeric
m6(1–236)/h6(237–494) subunits that link the N-terminal
domain of the m6 subunit to the transmembrane domains,
cytoplasmic loops, and C terminus of the h6 subunit. There is
functional expression represented by nicotinic agonist-induced
current responses in oocytes expressing nAChR m6(1–236)/
h6(237–494) and h4 subunits in combinationwithwild-type
nAChR h3 subunits (Fig. 6 and Table 4). The potentiation
rather than the dominant-negative suppression of 64*-
nAChR function in the presence of wild-type 3 subunits thus
seems to be influenced by6 subunit residues in theN-terminal
extracellular domain. Although not as strong from the perspec-
tives of nicotine potency and levels of functional expression, the
N-terminal extracellular domain of 6 subunits also influences
gain-of-function effects of mutant 3V9S subunits on 64*-
nAChR, including susceptibility to spontaneous opening sensi-
tive to open channel block (Table 3).
Region(s) Apart from the N-terminal Domain and First Three
Transmembrane Domains of nAChR 6 Subunits Seem to Be
FIGURE 5. Evidence for spontaneous opening of 64*-nAChR containing mutant 3V9S or 3V13S subunits. A, concentration-response curves (ordi-
natemeannormalized current S.E.; abscissa ligand concentration in logM) are shown for apparent outward current responses as follows:A, to atropine
for oocytes expressing h6h4h3V9S- (E); h6h4h3V13S- (F); m6m4m3V9S- (E); m6m4m3V13S- (F); or m6h4h3V9S- () nAChR (note that
curves are superimposable for oocytes expressing h6h4h3V9S- or m6h4h3V9S-nAChR), or B, to mecamylamine for oocytes expressing
h6m4m3V9S- (); (m6(1–350)/h6(351–494))h4h3V9S- (E) or (m6(1–236)/h6(237–494))h4h3V9S- (F) nAChR. The interpretation is that coex-
pression withmutant 3 subunits produces nAChR that open spontaneously, producing a stable inward current that is progressively blocked in the presence
of increasing concentrations of antagonists acting as open channel blockers. See Table 3 for parameters.
Effects of3 Subunits on6*-Nicotinic Receptor Function
NOVEMBER 4, 2011•VOLUME 286•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 37983
 at ELSEV
IER BV
 on Septem
ber 19, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Required for the nAChRh3V9S Subunit to ExertGain-of-Func-
tion Effects on m6h2*-nAChR—Oocytes coexpressing
nAChR chimeric m6(1–236)/h6(237–494) or m6(1–350)/
h6(351–494) subunits with h2 subunits alone or in the pres-
ence of wild-type h3 or mutant h3V9S subunits do not
respond to nicotinic agonists (Table 4). These results indicate
that the ability of nAChR h3V9S subunits to exert gain-of-
function effects on m6h2*-nAChR (Table 2), unlike effects
on 64*-nAChR, must be influenced by regions aside from
those in the N-terminal domains and first three transmem-
brane domains of nAChR 6 subunits.
Residues in the nAChR6 Subunit That Influence Function of
6*-nAChR
Studies described above using hybrid 6*-nAChR and chi-
meric 6 subunits suggested that residues in the highly con-
served N-terminal domain of nAChR 6 subunits influence
effects of 3 subunits on 64*-nAChR function. It is thought
that productive agonist binding occurs at selected interfaces
between specific subunits in nAChR assemblies, more specifi-
cally in a pocket formed by loops A, B, and C on the  or
primary face of  subunits except for 5 and loops D, E, and F
on the or complementary face of neighboring subunits (2 or
4 in the central or autonomic nervous systems as partners to
2, 3, 4, or 6 subunits, 7 in 7-nAChR homomers, and 
or  subunits as partners to 1 subunits in muscle-type
nAChR). Consideration of the alignment of mouse and
human 6 subunit amino acid sequences (Fig. 1) pointed us
to residues in loop A (h6 Lys-114) but also in loops D (h6
Asn-91 and Lys-94) and E (h6 Asn-143 and Met-145). Each
of these residues in the nAChR h6 subunit was mutated to
their counterpart in the nAChR m6 subunit individually or
in specific combinations (i.e. h6N91K, h6K94R, h6K114N,
h6N143D, h6M145V, h6N91KK94R, and h6N143DM145V;
see Fig. 1).
Residues at Positions 143 and 145 in the N-terminal Domain
of nAChR 6 Subunits Influence Effects of nAChR 3 Subunits
on 64*-nAChR Function—Coexpression of the double
mutant h6N143D/M145V subunit (but not any other single point
mutations or the h6N91K/K94R doublemutation) with h4 sub-
units yields oocytes responding to 100 M nicotine (mean 
S.E. peak response 35 12 nA; Fig. 7A). When the same set
of mutant h6 subunits are coexpressed with nAChR h4 and
h3 subunits, significant and reproducible peak current
responses (S.E.) to 100 M nicotine are obtained only for
h6N91Kh4h3-nAChR (28  4 nA), h6N143Dh4h3-
nAChR (31  5 nA), and double mutant h6N143D/M145V-
h4h3-nAChR (74 11 nA; Fig. 7A). However, only nAChR
FIGURE6.FunctionalpropertiesofnAChRcontaining chimeric6 subunits.A, concentration-response curves (ordinatemeannormalized current S.E.;
abscissa ligand concentration in logM) are shown for responses tonicotine for oocytes expressingnAChRchimericm6(1–350)/h6(351–494) subunits (A)
or m6(1–236)/h6(237–494) subunits (B) with h4 subunits alongwith either h3 (f) or h3V9S (E) subunits. A leftward shift in the nicotine concentration-
response curve is evident for functional nAChR containing h3V9S subunits relative to nAChR containingwild-type h3 subunits (p 0.0001;7–9-fold). See
Table 4 for parameters.
TABLE 4
Parameters fordrugactionatnAChRcontainingchimericmouse/human6subunits andhuman2or4subunits aloneor in combinationwith
wild-type or mutant human 3 subunits
Potencies (micromolar EC50 values with 95% confidence intervals for nicotine effects or micromolar IC50 values with 95% confidence intervals for mecamylamine effects),
Hill coefficients (nH S.E.), mean S.E. peak response (Imax in nA) and concentrations where maximal peak current amplitudes (Imax) are achieved (in M) are provided
for the indicated agonist (nicotine) or antagonist (mecamylamine) acting at nAChR composed of the indicated subunits derived from the specified species and from the
indicated number of independent experiments (n) based on studies as shown in figures.1 or2 indicates a significant (p  0.05) increase or decrease, respectively, in
potency of or peak response elicited by the indicated agonist at the indicated nAChR subtype relative to nAChR containing the same subunits but in the absence of the
indicated3 subunit.Œ or indicates a significant increase or decrease, respectively, in indicated agonist potency or peak response at the indicated nAChR subtype relative
to nAChR containing the same subunits in the presence wild-type 3 subunits. Note that no response or very rare and then small responses were seen for the following
subunit combinations (n 4–9 each) to nicotine: m6(1–350)/h6(351–494) h2 alone or with h3 or h3V9S; m6(1–236)/h6(237–494) h2 alone or with h3
or h3V9S subunits.  indicates that absent or inconsistent functional responses in two-electrode voltage clamp studies precluded determination of the parameter of
interest.
Drug nAChR subunit combinations
Potency Peak response
n EC50 or IC50 (95% CI) nH S.E. nH n Mean Imax S.E. Imax concentration
M nA M
Nicotine m6(1–350)/h6(351–494) h4 9 – – 9 – –
m6(1–350)/h6(351–494) h4 h3 4 12 (8.6–15)1 1 0.4 4 33 141 100
m6(1–350)/h6(351–494) h4 h3V9S 4 1.8 (1.3–2.6)1Œ 1.4 0.14 4 140 481Œ 100
m6(1–236)/h6(237–494) h4 3 – – 3 – –
m6(1–236)/h6(237–494) h4 h3 5 15 (9.5–22)1 1.5 0.48 5 120 261 100
m6(1–236)/h6(237–494) h4 h3V9S 4 1.6 (0.97–2.6)1Œ 0.74 0.11 4 500 1601Œ 100
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containing the double mutant h6N143D/M145V subunit show
the peak current response potentiation by coexpressionwith3
subunits seen for m6h4h3-nAChR.
There is some level of functional response (peak  S.E.) to
100 M nicotine in oocytes coexpressing nAChR h4 and
h3V9S subunits in combination with h6N91K (25  6 nA),
h6(K94R) (16  3 nA), h6N143D (42  12 nA), h6M145V
(15  1 nA), or h6N91KK94R (15  1 nA) subunits (Fig. 7B),
but none of these combinations yields responses like those seen
for m6h4h3V9S-nAChR (1600 nA) or even (m6(1–
236)/h6(237–494))h4h3V9S-nAChR (140 nA) or
(m6(1–350)/h6(351–494))h4h3V9S-nAChR (500 nA).
Curiously, coexpression of nAChR h4 and h3V9S with
nAChR h6K114N subunits yields oocytes giving outward cur-
rent responses to 100 M nicotine (data not shown). Signifi-
cantly, only coexpression of double mutant h6N143D/M145V
subunits in combination with h4 and h3V9S subunits yields
oocytes giving peak current responses (490  63 nA) to 100
M nicotine that rival those of m6h4h3V9S- or
(m6(1–236)/h6-(237–494))h4h3V9S-nAChR.
Upon coexpressionwith h4 and h3V9S subunits, exposure
to 1 mM mecamylamine elicits apparently outward currents in
oocytes also injected with h6N91K (17 8 nA), h6K94R (14
5 nA), h6N143D (90  11 nA), h6M145V (31  5 nA), or
h6N91K/K94R (13  3 nA) subunit cRNA (Fig. 7C). However,
the largest apparently outward current is mediated by
h6N143D/M145Vh4h3V9S-nAChR (270  150 nA; Fig. 7C),
with an amplitude comparable with that seen for atropine
action on m6h4h3V9S-nAChR and 5-fold higher than
that seen formecamylamine action at (m6(1–236)/h6-(237–
494))h4h3V9S-nAChR. This indicates that there is some
spontaneous opening of receptors containing the indicated
subunits.
These findings indicate that nAChR 6 subunit residues at
positions 143 and 145 influence the ability to form functional
64-, 643-, and 643V9S-nAChR, dictate whether
3 subunits have dominant-negative suppression or gain-of-
function effects, and are involved in gain-of-function effects
of mutant 3V9S subunits on 64*-nAChR. Clearly,
wild-type or mutant 3 subunits are incorporated into func-
tional 64*-nAChR complexes when residues at positions
143 and 145 are the same as those in the nAChR m6
subunit.
Residues at Positions 91 and 143 Are among Those in the
N-terminal Domain of nAChR 6 Subunits That Influence
Effects of nAChR 3V9S Subunits on 62*-nAChR Function—
Although studies with chimeric nAChR 6 subunits suggested
that residues C-terminal to the third transmembrane domain
influenced assembly of functional 623V9S-nAChR, we also
examined the effects of m6 subunit-like mutations in the
N-terminal extracellular domain of the h6 subunit on the
function of nAChR produced in oocytes upon coexpression
with h2 subunits alone or in addition to h3 or h3V9S sub-
units. Coexpression of h6N91K, h6K94R, h6N143D, h6M145V,
h6N91KK94R, or h6N143DM145V subunits with nAChR h2
subunits alone or in combination with wild-type h3 subunits
does not result in consistent production of function upon expo-
sure to 100 M nicotine (data not shown). However, and sur-
prisingly, coexpression of h6N91K, h6K94R, h6N143D,
h6M145V, or h6N143D/M145V subunits with h2 and h3V9S
subunits resulted in production of oocytes giving inward cur-
rent responses to 100 M nicotine or apparently outward cur-
rent responses to 1 mM mecamylamine (Fig. 8). Oocytes coex-
pressing h6N91KK94R subunits with h2 and h3V9S
subunits failed to produce consistent response to 100 M nico-
tine or outward current responses to 1 mM mecamylamine
(data not shown). These results suggest that the indicated tri-
nary complexes are formed and have some function, although
levels of functional expression and spontaneous channel open-
ing are less than 1/3rd of that seen form6h2h3V9S-nAChR.
DISCUSSION
Patterns of nAChR 6 and 3 subunit coexpression in pri-
mates or rodents in vivo (15–17) and clear evidence of the func-
tional importance of native 6*-nAChR in the same species
(2–7, 18, 19) suggest that 63*-nAChR exist in functional
FIGURE 7. Effects of nAChR 6 subunit N-terminal domain amino acid
substitutions on functional responsiveness of 643-nAChR to nico-
tinic ligands. A and B, mean (S.E.) peak inward current responses upon
exposure (10 s) to 100Mnicotine (10 s exposure; ordinate) fromoocytes (n
4) voltage-clamped at70 mV and heterologously expressing the indicated
nAChR subunits. C, mean (S.E.) apparent peak outward current responses
upon exposure (10 s) to 1000 M mecamylamine (10 s exposure; ordinate)
from oocytes (n  4) voltage-clamped at 70 mV and heterologously
expressing the indicated nAChR subunits. *, p  0.05; **, p  0.01; ***, p 
0.001. h6(N143D) subunits are present in h6h4*-nAChR that have the
largest amplitude responses to nicotine and the largest amplitude for
mecamylamine-sensitive spontaneous openings, whether in the presence of
wild-type or mutant h3 subunits.
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forms that should be evident upon heterologous expression.
However, some of the prior studies of heterologous expression
of6*-nAChR indicated that hybrid receptors containing com-
binations of chicken and human nAChR subunits exhibit some
level of function, although all-human or all-chicken 6*-
nAChRdidnot (10).Moreover, and although these studieswere
done using oocytes manipulated to express disproportionate
ratios of subunits, incorporation of nAChR h3 subunits pres-
ent in presumed excess have a dominant-negative effect on the
function of all-human22*-,24*-,32*-,34*-,42*-,
or 44*-nAChR that is reversed upon substitution of mutant,
h3V9S for wild-type 3 subunits (12). Similar effects are men-
tioned (but not described in detail) of effects of wild-type or
mutant 3 subunits on function of 62*- and 64*-nAChR
(11). Interestingly, other studies using chimeric (6/3) sub-
units (containing theN-terminal domain of the nAChR6 sub-
unit substituting for that of the otherwise3 subunit) instead of
wild-type 6 subunits showed potentiating effects of wild-type
3 subunit coexpression on 6*-nAChR (8). Here, we have
extended these lines of studies to make novel and sometimes
surprising findings that help to crystallize our cumulative
understanding of 63*-nAChR function.
One of the conclusions from this work is that nAChR wild-
type ormutant3 subunits can incorporate into heterologously
expressed 64*-nAChR, where they predominantly exert
dominant-negative (wild-type 3 subunits) or gain-of-function
(mutant 3V9S or 3V13S subunits) effects, respectively. The
abilities of wild-type m3 subunits to mimic dominant-nega-
tive effects of wild-type h3 subunits suggests that 3 subunits
from either species have the same features needed for negative
dominance or gain-of-function. These findings are of interest
for nAChR structure-function relationships (see below), but
their physiological significance is tempered because there are
few brain regions in rodents where all three subunits are
expressed, although the circumstance may be different in pri-
mates, whichmight express higher levels of 4 subunits and do
so more broadly (15, 17–19).
It is clear froma variety of studies, including those done using
knock-out animals and nicotinic agonist-activated neurotrans-
mitter release assays (2, 4), that naturally expressed mouse
nAChR containing 6, 3, and 2 subunits seem to be func-
tional and sensitive to blockade by specific -conotoxins (7),
but there are fewer indications that human 623*-nAChR
are functional when naturally or heterologously expressed.
Thus, we wondered whether there simply might be species-
specific differences in the ability to heterologously express
623*-nAChR, and so we chose to see if murine 623*-
nAChR could be functionally expressed when equivalent
human receptors could not. However, we realized very similar
outcomes in our studies of all-human or all-mouse 623*-
nAChR, even when 3 subunits had gain-of-function muta-
tions and despite success of the gain-of-function strategy when
applied to 643*-nAChR. The inability of wild-type or
mutant 3 subunits to influence function of 62*-nAChR
confounds the ability to make inferences about assembly of
the indicated subunits. Also, the lack of function of
h6h2h3V9S- or h6h2h3V13S-nAChR observed in this
work is in contrast to the observation by Broadbent et al. (12)
that human623V9S-nAChR are functional and to our find-
ings that h6h4h3V9S- or h6h4h3V13S-nAChR are
functional.
We tried to solve this problem by using two different
approaches. One approach involved switching sequences
between m2 and h2 subunits, but this did not influence
the ability of wild-type or mutant 3 subunits to affect func-
tion of 62*-nAChR, although h6m4h3V9S- and
m6h4m3V9S-nAChR were functional. The other ap-
proach entailed switching sequences between m6 and h6
subunits and surprisingly showed that m6h2h3V9S- and
m6h4h3- nAChR are functional.
The persisting lack of function seen for all-human or all-
mouse62- or623-nAChR suggests that native andphys-
iologically relevant receptors likely contain an additional
assembly partner, perhaps 4 or 3 subunits. Another possibil-
ity that would bemuchmore difficult to test is that oocytes, but
not the right kinds of nerve cells, lack chaperones that facilitate
assembly and functional expression of 623*-nAChR.
However, success in formation of functional, hybrid
m6h2h3V9S- and m6h4h3-nAChR indicated that fea-
tures of6 subunits influence the function or functional assem-
bly of 63*-nAChR. Chimeric 6 subunits containing differ-
ent length segments of them6 subunit fused to otherwise h6
subunits localized key determinants involved in effects of 3
subunits on 64*-nAChR function to the N-terminal extra-
cellular domain of the nAChR 6 subunit but gave little initial
indication that the same region influenced effects of 3 sub-
units on 62*-nAChR function. Our studies of 62*-nAChR
also suggest that the cytoplasmic loop (and perhaps, although
less likely, the fourth transmembrane domain and the C-termi-
nal tail) of the6 subunit can influence functional expression of
receptors and their interactions with 3 subunits, perhaps con-
FIGURE 8. Effects of nAChR 6 subunit N-terminal domain amino acid
substitutions on functional responsiveness of 623-nAChR to nico-
tinic ligands. A,mean (S.E.) peak inward current responses upon exposure
(10 s) to 100 M nicotine (10 s exposure; ordinate) from oocytes (n 4) volt-
age-clamped at70mVandheterologously expressing the indicated nAChR
subunits. B, mean (S.E.) apparent peak outward current responses upon
exposure (10 s) to 1000 M mecamylamine (10 s exposure; ordinate) from
oocytes (n 4) voltage-clamped at70 mV and heterologously expressing
the indicated nAChR subunits. *, p  0.05; **, p  0.01; ***, p  0.001.
h6(N143D) subunits are present in h6h2*-nAChR that have the largest
amplitude responses to nicotine and the largest amplitude for mecamyl-
amine-sensitive spontaneousopenings,whether in thepresenceofwild-type
or mutant h3 subunits.
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sistent with the observations by Kuryatov et al. (8) who used
chimeric subunits possessing intracellular domains of the 3
instead of 6 subunit.
Site-directedmutagenesis work, simplified to some extent by
the remarkable homology between human and mouse nAChR
6 subunits, indicated that the function like that seen in hybrid
receptors occurring for h6N143D/M145Vh4-nAChR is poten-
tiated in the presence of wild-type h3 subunits and is further
potentiated upon substitution of mutant h3V9S for wild-type
h3 subunits. These findings indicated that amino acid resi-
dues 143 and 145 in the 6 subunit are key determinants influ-
encing effects of 3 subunits on 64*-nAChR function. m6
differs from h6 by having a negatively charged rather than a
polar side chain at position 143 and a residue with a slightly
higher hydrophobicity and smaller side chain volume at posi-
tion 145. These differences might enhance interactions
between 6 and 3 and/or 4 subunits. These residues are in
loop E on the or complementary face of the 6 subunit that
would be involved in presumed interactions with residues on
the or primary faces of the neighboring 3 subunit and/or of
the neighboring4 subunit in a complex that has the presumed
(counterclockwise when viewed from the extracellular space)
arrangement as follows: 3:6:4:6:4.
Neighboring () face residues in loop E at consensus positions
139, 141, 147, and 149 (Leu, Lys, Thr, and Thr, respectively,
preserved across mammalian 6 subunits, although chickens
have Pro-141; see Fig. 9) have been implicated in agonist bind-
ing based largely on mutagenesis or structural studies of mus-
cle-type or 7-nAChR (20). It is unexpected that agonist bind-
ingwould occur at3:6 or4:6 subunit interfaces, as it
would be expected to be confined to 6:4 (or 6:2)
interfaces (but see Moroni et al. (21) for evidence that nAChR
2:4 interfaces are engaged in allosteric effects of Zn2). It
is possible that 3:6 and/or 4:6 subunit interfaces in
the vicinity of loop E are important for subunit assembly lead-
ing to closure of functional cell-surface expression of 643-
nAChR complexes, and distal involvement of 3:6 and
4:6 subunit interfaces in ligand binding or transduction of
ligand binding to channel gating cannot be discounted. It is
notable thatmouse and chicken6 subunits share the presence
of aspartate at position 143 as opposed to the human aspara-
gine, perhaps more deeply implicating that residue in the func-
tion of hybrid 6*-nAChR.
Although studies using chimeric mouse/human 6 subunits
did not initially implicate the N-terminal region in interactions
with3 subunits, consistent with the site-directedmutagenesis
work at some of the N-terminal domain residues investigated,
coexpression of nAChR h6N91K or h6N143D subunits
together with nAChR h2 and h3V9S subunits resulted in
production of functional receptors as evident by inward current
responses to nicotine and apparently outward current re-
sponses to mecamylamine. The h6N143D single mutation also
accounted for effects when it was coupled with the more con-
servative, h6M145V mutation. Although absolute levels of
function were not particularly high andwere just 1/3rd of those
for hybrid m6h2h3V9S-nAChR, again suggesting as did
chimeric subunit studies that residues C-terminal to the third
transmembrane domain play a role in influencing effects of 3
subunits on 62*-nAChR function, these studies implicate
sites involved in formation of functional 623-nAChR.
Aside from the considerations already described above about
residue 143 in the E loop of the 6 subunit engaging in interac-
tions with neighboring3 or, in this case,2 subunits, there are
potential influences of the introduction of a positively charged
instead of a polar side chain at position 91 that could influence
effects of 3 subunits on 62*-nAChR. Interestingly, residue
91 is in loop D and on the  face of the 6 subunit, slightly
C-terminal to residues at positions 85 and 87 (Trp and Arg,
respectively, preserved acrossmammalian, chicken, and fish6
subunits). Residue 91 is an asparagine in primates, cows, and
chickens but is a lysine in rats andmice (Fig. 9). It, as opposed to
residue 143,might not account for differences between chicken
and human 6 subunits in hybrid receptors, but it seems to
contribute to differences between mouse and human 6 sub-
units. Perhaps the incomplete (relative to hybrid 623V9S-
nAChR) potentiation of 62*-nAChR function is because the
changes in position 143 reflect influences on3:6 and4:
6 subunit interactions but not 2:6 subunit interac-
tions. Reciprocally, changes in position 91 might have effects
only because they influence 2:6 and not 4:6 subunit
interactions. Again, given that it would be unexpected for ago-
nist binding to occur at 3:6 or 2:6 subunit inter-
faces, as opposed to at 6:2 interfaces, changes in residues
in loops D and E probably affect assembly and closure of func-
tional 623-nAChR pentamers, although they could have
allosteric effects on ligand binding and/or coupling to channel
FIGURE 9. Multiple sequence alignment of nAChR 6 subunit proteins from several species (GenBankTM accession number NP_004189.1 (human,
Homo sapiens), NP_001029266.1 (chimpanzee, Pan troglodytes), XP_001099152.1 (monkey.Macacamulatta), NP_476532.1 (rat, Rattus norvegicus),
NP_067344.2 (mouse,Mus musculus), XP_584902.3 (cow, Bos taurus), NP_990695.1 (chicken, Gallus gallus), and NP_001036149.1 (zebrafish, Danio
rerio)). Numbering begins at translation start methionine of human nAChR 6 subunit protein and is shown in the N-terminal domain region of interest.
Symbols below sequences indicate fully (*), strongly (:) or weakly (.) conserved residues, and underlining in boldface indicates numbered residues given prime
attention in human nAChR 6 subunit mutagenesis studies.
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opening (e.g. see Ref. 21), maybe even serving as coagonist-
binding sites.
Finally, effects of atropine or mecamylamine interpreted as
that of 6*-nAChR showing gain-of-function have a significant
probability of spontaneous channel opening that is abated by
atropine- or mecamylamine-mediated open channel block.
Gain-of-function effects due to mutations occurring at the 9-
or 13-positions in the 3 subunit second transmembrane
domain have largely similar effects but in some cases yield func-
tional receptors with different agonist sensitivities, suggesting
subtleties in coupling between ligand binding and channel
opening.
In conclusion, our results provide evidence that wild-type 3
or mutant 3V9S or 3V13S subunits can incorporate into and
either suppress/abolish or enhance function of 64*-nAChR
but not 62*-nAChR. These observations, along with the
demonstration that 3 subunits can form functional receptors
with 7 subunits (22) and that 3V273T subunits participate in
formation of34*-nAChR (23, 24), help to define nAChR sub-
types capable of containing3 subunits, thus providing insights
into roles of 3*-nAChR in nicotinic signaling. However, there
remain puzzles about the makeup of functional, all-human or
all-mouse6*-nAChR, especially63*-nAChR.Nevertheless,
our results provide further evidence that wild-type and/or
mutant 3 subunits not only form functional receptors in com-
bination with 6 subunits but also influence 6*-nAChR func-
tion. We also show for the first time that dominant-negative
suppression or potentiation of 64*-nAChR upon heterolo-
gous coexpression with wild-type 3 subunits is influenced in
hybrid receptors and in the presence of chimeric 6 subunits in
ways affected by selected residues that unexpectedly are found
on the N-terminal extracellular domain face of 6 subunits.
These and additional residues influence effects of mutant 3
subunits on function of 62*-nAChR. The current findings
suggest that the molecular description of functional nAChR
is incomplete and that novel interfaces (i.e. other than the
consensus interface thought to be involved in productive
agonist binding, 6:2 or 6:4) between nAChR sub-
units play heretofore unappreciated roles in receptor assem-
bly, ligand recognition, and/or function. Finally, the devel-
opment of oocytes that express 63*-nAChR and the
prospect that cell lines also containing the same assemblies
in functional forms provide potentially useful tools for devel-
opment of 6*-nAChR-selective or -specific ligands, with
the caveat that any 6*-nAChR-containing subunits with
gain-of-function properties or chimeric subunits may have
different sensitivities for agonists or perhaps other types of
ligands than 6*-nAChR composed of fully wild-type sub-
units. This is important due to the growing interest in func-
tional 63*-nAChR based on their demonstrated or per-
ceived importance in locomotion, reward and reinforcement
behavior, schizophrenia, and Parkinson disease (2, 15, 25).
Perhaps of high significance is the association of single
nucleotide polymorphisms in the genes (CHRN
6 and
CHRN3) encoding 6 and 3 subunits with nicotine depen-
dence, number of quit attempts, and subjective responses to
nicotine (26–30). Studies as described here are essential for
an improved understanding of structure and function and
ultimately of biological roles of 63*-nAChR.
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